Clinical data, including results from the March 2026 Phase 3 TRANSCEND-T2D-1 trial, suggests that retatrutide exhibits properties relevant to weight regulation and glycemic modulation in research models
The Wegovy pill is approved for adults (not pediatrics) and comes with highly specific dosing and absorption instructions
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors, distinguishing it from single agonists (Semaglutide) and dual agonists (Tirzepatide)
Unfortunately, the effects of such treatment on appetite reducing action of leptin have not been tested
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Det er ogs viktig forst at bonusordninger ikke er gratis penger